Screener
Maze Therapeutics MAZE Other operating expenses
Other operating expenses at other companies
Other financials
Where this comes from
Reported directly by Maze Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingExpenses.
The source filing: Maze Therapeutics’s 10-Q, filed August 11, 2026.
- Filed
- Aug 11, 2026, 4:48 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-344903
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Operating expenses: | ||||
| Research and development | 34,940 | 28,108 | 69,088 | 55,688 |
| General and administrative | 13,095 | 8,366 | 25,500 | 16,187 |
| Total operating expenses | 48,035 | 36,474 | 94,588 | 71,875 |
| Loss from operations | (48,035) | (36,474) | (74,588) | (71,875) |
| Other income (expense): | ||||
| Interest and other income, net | 4,239 | 2,795 | 7,450 | 5,410 |
| Interest expense | (931) | — | (1,797) | — |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Maze Therapeutics's other operating expenses?
- Maze Therapeutics (MAZE) reported other operating expenses of $48.04M in Q2 2026.
- How has Maze Therapeutics's other operating expenses changed year-over-year?
- Maze Therapeutics's other operating expenses increased by 31.7% year-over-year, from $36.47M to $48.04M.
- What does other operating expenses mean?
- Residual operating expenses not classified into specific categories, serving as a catch-all for miscellaneous operating costs.
Ask your AI about Maze Therapeutics's other operating expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude